A miR boost enables acute leukemia cells to matureApril 03, 2009COLUMBUS, Ohio - A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development. The study discovered how the miR reactivates silenced genes, which enables the leukemic cells to differentiate and mature, important steps that precede their death. The findings suggest that miR-29b could be a potent treatment for AML. The molecule blocks the action of three enzymes, all of which add small chemical units called methyl groups to genes. The addition of the units locks genes down tight and takes them out of action. By blocking the enzymes, the miR removes the methyl groups from genes, a process called demethylation, which then reactivates them. The study is reported online in the journal Blood. "We show that miR-29b is a powerful demethylating agent and provides a rationale for developing this molecule as a possible drug for the treatment of AML, alone or in combination with other agents," says first author Dr. Ramiro Garzon, a hematologist-oncologist and assistant professor of internal medicine at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute. Garzon notes that the miR might prove to be more potent than current demethylating agents, which block only one of the three enzymes inhibited by miR-29b. "The action of miR-29b is more complete," he says. Earlier research by the same investigators using lung cancer cells showed that miR-29b targets two enzymes, DNMT3A and DNMT3B, that both add the chemical units (methyl groups) to genes. When the researchers raised the level of miR-29b in leukemic cells, the amount of a third enzyme, called DNMT1, fell. "We discovered that this miR blocks DNMT1 also, but indirectly," Garzon says. The miR, it turns out, targets another protein - called Sp1 - that boosts production of the DNMT1 protein. Thus, low levels of the miR may result in lots of Sp1 protein and of DNMT1, which busily adds the chemical units that silences genes. High levels of the miR, on the other hand, may keep the amount of Sp1 low, so there is little DNMT1 and much less gene silencing. "Our paper explains why this miR is a powerful demethylating agent," Garzon says. "It shows that putting this miR back into leukemia cell lines and leukemia cells from patients causes a drop in global DNA methylation and reactivates protective tumor suppressor genes, which allows the cells to differentiate and mature." Ohio State University Medical Center |
|||||||||||||||||||||
| Related Leukemia Current Events and Leukemia News Articles First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Drug shows promise in treating dangerous complication of erectile disorder Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Brain tumors in childhood leave a lasting mark on cognition, life status Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Propolis has proved to be a product with ability to have beneficial effects for health Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. Chemosensitivity of cancer cells depends on their protein dependency Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB). Drug could provide first treatment for scleroderma Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. New chromosomal abnormality identified in leukemia associated with Down syndrome Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome. Governor recognizes stem cell research at Einstein Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. More Leukemia Current Events and Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||